One new and seven known diterpenes were identified from an antibacterial chromatographic fraction of Taxodium ascendens.
Bacterial resistance to antibiotics is increasing, and the need for new antibiotics is clear. In our search for drug leads against Grampositive bacteria, we hypothesized that plants growing in swampy areas would be challenged by bacterial colonization, and would therefore have evolved antibacterial compounds. We thus looked at our library of chromatographic fractions of plant extracts and identified 2640 from plants that were collected in Florida. These fractions (which typically contain a mixture of 1-5 compounds) were screened for inhibition of Staphylococcus aureus. Of these fractions, 50 showed > 90% inhibition at 70 µg/mL, and their components were isolated by semi-preparative HPLC.
Taxodium is a genus of trees of the Cupressaceae family, which includes bald cypress, pond cypress, and Montezuma cypress [1a]. Pond cypress has been labeled both as a separate species (T. ascendens) and as a botanical variety of bald cypress (T. distichum var. imbricarium). Given their tolerance for wet, dry, and saline conditions, Taxodium species are candidates for phytoremediation [1b] . From the antibacterial chromatographic fractions of pond cypress, we isolated one new diterpene named cupressatetrol (1), and the known diterpenes demethylcryptojaponol (2), 6-hydroxysalvinolone (3), hydroxyferruginol (4), hinokiol (5), sugikurojin A (6), 6α-hydroxy-demethylcryptojaponol (7), and pinusolidic acid (8) (Figure 1 ). The HRESIMS of 1 indicated a molecular formula of C 20 H 32 O 5 . The 1 H spectrum of 1 contained signals for two doublet methyl groups and three singlet methyl groups, similar to the spectra of 2, 3, and 7. Unlike the other spectra, however, the 1 H spectrum of 1 had signals for 3 oxymethines ( H 4.54, 3.77, 4.48), but lacked any aromatic proton signals. This suggested that 1 does not contain an aromatic ring. Examination of the COSY, HSQC, and HMBC spectra established the molecule's connectivity and placed the oxymethines at C-7, C-12, and C-14. Specifically, HMBC correlations from H-7 ( H 4.54) to both C-8 ( C 152.7) and C-9 ( C 142.0) supported placement of one hydroxyl at C-7. HMBC correlations from the doublet methyls to an oxygenated carbon (C-13,  C 75.2) placed an additional hydroxyl at C-13. Placement of the ketone at C-11 was supported by an HMBC correlation from H-12 ( H 3.77) to C-11 ( C 201.0) and by the chemical shifts of C-8 suggested that these two protons are on the same face of the C-ring, but the relationship to the B-ring was not apparent, and there was not enough material to attempt derivatization.
Compounds 1-8 were tested for activity in an initial screen against MSSA (data not shown); of these, 2-5 were active at ≤ 8 µg/mL. The four active compounds were then tested against clinical isolates of MRSA. Each of these showed potent activity against one or more of the clinical isolates (Table 2) . To the best of our knowledge, this is the first report of MRSA activity for 3-5. Yang et al. [2a] reported MICs of 4-6 µg/mL for 2 against three MRSA strains different from those tested here. Importantly, they also reported an efficient synthesis of 2 and several other analogues, demonstrating that these compounds are synthetically accessible. Thus, compounds 2-5 are attractive targets for further drug development efforts for MRSA. The combined extracts were dried under vacuum to yield 18 g dry extract. Preparation of screening fractions from the extract, using normal phase flash chromatography followed by reversed phase preparative HPLC, was carried out as described previously [2c]. Briefly, 1 g of the extract was fractionated by flash chromatography using a 50 g silica flash column eluted with 300 mL each of hexanes-EtOAc (3:1, v/v, fraction 1), hexanes-EtOAc (1:1, v/v, fraction 2), EtOAc (fraction 3), EtOAc-MeOH (7:3, v/v, fraction 4), and EtOAc-MeOH (1:1, v/v, fraction 5). Each flash fraction was further fractionated into 40 preparative HPLC fractions using columns and gradients tailored to the flash fraction. The active fractions described here came from flash fraction 3, and were prepared using a Thermo Betasil preparative C18 column (21.2 x 100 mm) eluted at 20 mL/min with the following gradient: 2 min at 20% B, then a 34 minute gradient to 85% B, then 6 min at 85% B. Solvent A was 0.05% TFA (v/v) in water and solvent B was 0.05% TFA (v/v) in MeCN.
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Isolation of individual compounds:
To prepare enough material to identify and assay the individual compounds from the active fraction, the remaining 17 g of extract was fractionated using an open Si column (5 × 47 cm) eluted with hexanes (650 mL), hexanes-EtOAc (3:1, v/v, 600 mL), hexanes-EtOAc (1:1, v/v, 1000 mL), and EtOAc (1000 mL). Material that eluted in the hexanes-EtOAc (1:1) fraction was subjected to preparative HPLC in 100 mg portions, as described above. Material eluting between 23 and 27 min was pooled from several runs. From this pool, compounds 1-8 were isolated using semi-preparative HPLC with a Betamax Neutral C18 column (7.7 x 250 mm) eluted at 3 mL/min with 50% B for 5 min, followed by a 25 min gradient to 60% B, and then a 1 min gradient to 95% B. Solvents A and B are described above. Serial injections afforded 1 (20 µg, t R 5.1 min), 2 (2 mg, t R 22.5 min), 3 (130 µg, t R 31.0 min), 4 (60 µg, t R 15.5 min), 5 (50 µg, t R 19.0 min), 6 (20 µg, t R 13.0 min), 7 (20 µg, t R 24.0 min), and 8 (20 µg, t R 10.0 min).
Cupressatetrol ( Antibacterial assays: MSSA strain 25923 was obtained from ATCC and was used for initial screening of chromatographic fractions and purified compounds. For the assays, an overnight culture in trypticase soy broth was diluted 1:100 in cation-adjusted Mueller-Hinton broth, and incubated at 37°C until it reached an OD 600 of 0.2. The resulting culture was diluted 1:100 in medium and placed in a 96-well plate (10 6 CFU/mL, 100 µL/well). Chromatographic fractions were dissolved in DMSO, diluted in medium, and added to wells (100 µL/well) for a final concentration of 70 µg/mL (2 wells/fraction). Individual compounds were dissolved similarly and tested at serial ½ dilutions starting at 16 µg/mL (3 wells per dose). Gentamicin was used as a positive control. The plates were incubated for 24 h at 37°C, and growth inhibition was determined by the change in OD 600 at the end of the incubation period compared with control wells without compound. MRSA clinical isolates MRSA-106, MRSA-108, MRSA-109, MRSA-111, and MRSA-148 were provided by David Hunstad and described previously [2d,3] . MICs are reported as the minimum concentration that resulted in at least 90% inhibition.
Supplementary data: 1 H, 13 C, HSQC, HMBC, and ROESY spectra for compound 1.
